Ultrapurification of Biomacromolecules

生物大分子的超纯化

• 批准号: 9014119
• 负责人: Csaba Horvath
• 金额: $ 45.06万
• 依托单位: Yale University
• 依托单位国家: 美国
• 项目类别: Continuing Grant
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-09-01 至 1994-02-28
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9014119&HistoricalAwards=false
• 关键词: Ultrapurification; Biomacromolecules

The remarkable recent advances in genetic engineering now allow industrial-scale production of therapeutic proteins for human health care. With the introduction of new production methods have come immense purification challenges. In order to avoid untoward side effects of contaminants (many of which are as yet unknown), therapeutic proteins must be ultra-purified to levels beyond the scope of present technology. Thus, there is a great need for novel separation and purification techniques which may be applied on an industrial scale. This multi-investigator study is an effort to integrate several innovative technologies ısuch as High Performance Liquid Chromatography, (HPLC), electrophoresis, and supercritical-fluid based separations! to provide a basis for industrial ultrapurification of biomacromolecules. Applications of such new purification and separation technologies will be tested on recombinant tissue plasminogen activator, a life-saving therapeutic used in the treatment of heart attack victims.

最近基因工程领域的显著进步使人类保健治疗蛋白的工业化生产成为可能。随着新的生产方法的引入，带来了巨大的净化挑战。为了避免污染物的不良副作用(其中许多污染物尚不清楚)，治疗性蛋白质必须超提纯到超出目前技术范围的水平。因此，迫切需要可用于工业规模的新型分离纯化技术。这项多研究者的研究是一项努力整合ı的几项创新技术，如高效液相色谱法、电泳法和基于超临界流体的分离！为生物大分子的工业化超纯化提供依据。这些新的纯化和分离技术的应用将在重组组织型纤溶酶原激活剂上进行测试，重组组织型纤溶酶原激活剂是一种用于治疗心脏病发作患者的救命疗法。